Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on AngioDynamics and keeping the price target at $16.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yi Chen’s rating is based on AngioDynamics’ strong financial performance in fiscal 1Q26, where the company exceeded expectations in both net sales and net loss. The Med Tech segment showed significant growth, particularly in product lines such as Auryon, AngioVac, AlphaVac, and NanoKnife disposables. This robust performance led management to raise their full-year FY26 guidance, projecting increased net sales and adjusted EBITDA.
Additionally, ongoing clinical trials, such as the AMBITION BTK and RECOVER-AV trials, are expected to enhance market adoption of AngioDynamics’ Med Tech products. The company also anticipates positive free cash flow for FY26, supported by a solid cash position. These factors combined suggest a promising outlook for AngioDynamics, justifying the Buy rating and a $16 price target.
Chen covers the Healthcare sector, focusing on stocks such as VolitionRX, Anixa Biosciences, and Formycon AG. According to TipRanks, Chen has an average return of -4.7% and a 43.61% success rate on recommended stocks.
In another report released on October 3, Lake Street also reiterated a Buy rating on the stock with a $24.00 price target.